This is further underscored by promising results in related models, such as MOG-specific CAR-Treg and MBP-specific TCR-Treg for MS as well as the FVIII-specific CAR-Treg and FVIII-specific TCR-Treg to tolerate rFVIII in Haemophilia A patients. This evidence concerns the gene F8 and myeloid sarcoma.